CA19-9 kinetics during systemic chemotherapy in patients with advanced or recurrent biliary tract cancer

被引：6

作者：

Takahara, Naminatsu ^{[1
]}

Nakai, Yousuke ^{[1
]}

Isayama, Hiroyuki ^{[2
]}

Sasaki, Takashi ^{[3
]}

Saito, Kei ^{[1
]}

Noguchi, Kensaku ^{[1
]}

Suzuki, Tatsunori ^{[1
]}

Nakamura, Tomoka ^{[1
]}

Sato, Tatsuya ^{[1
]}

Ishigaki, Kazunaga ^{[1
]}

Hakuta, Ryunosuke ^{[1
]}

Takeda, Tsuyoshi ^{[1
]}

Uchino, Rie ^{[1
]}

Mizuno, Suguru ^{[1
]}

Kogure, Hirofumi ^{[1
]}

Tada, Minoru ^{[1
]}

Koike, Kazuhiko ^{[1
]}

机构：

[1] Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan

[2] Juntendo Univ, Grad Sch Med, Dept Gastroenterol, Tokyo, Japan

[3] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Gastroenterol, Div Hepatobiliary & Pancreat Med, Tokyo, Japan

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2017年 / 80卷 / 06期

关键词：

Biliary tract cancer; Carbohydrate antigen 19-9; Chemotherapy; Prognostic factors; Retrospective study; CARBOHYDRATE ANTIGEN 19-9; PLUS GEMCITABINE; SURVIVAL; CA-19-9; CISPLATIN; MULTICENTER; PREDICTOR; S-1; CEA;

D O I：

10.1007/s00280-017-3456-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose The role of carbohydrate antigen 19-9 (CA19-9) kinetics in patients with biliary tract cancer (BTC) receiving chemotherapy remains to be elucidated. Methods A total of 185 advanced or recurrent BTC patients receiving a first line chemotherapy between January 2006 and March 2016, were retrospectively studied. Serum CA19-9 was measured at baseline and after two cycles of chemotherapy, and patients were categorized based on CA19-9 response: CA19-9 decrease group (>= 30% decrease), stable group (< 30% decrease and < 20% increase) and increase group (>= 20% increase). The associations of CA19-9 response with radiological tumor response, progression-free survival (PFS) and overall survival (OS) were investigated. Results There was a statistically significant association between CA19-9 response and radiological tumor responses (p < 0.001). The median PFS and OS were significantly different among three groups according to CA19-9 response: PFS of 8.0, 5.7 and 3.5 months in CA19-9 decrease, stable and increase groups (p < 0.001) and OS of 18.8, 16.0 and 7.5 months in CA19-9 decrease, stable and increase groups, respectively (p < 0.001). Multivariate analyses showed that CA19-9 response was prognostic both of OS and PFS in addition, to CA19-9 at baseline, and performance status. Conclusion CA19-9 kinetics after the first two cycles of a first line chemotherapy was a prognostic factor for OS and PFS in patients with advanced and recurrent BTC.

引用

页码：1105 / 1112

页数：8

共 28 条

[1]

Buyse M, 1996, STAT MED, V15, P2797, DOI 10.1002/(SICI)1097-0258(19961230)15:24<2797::AID-SIM290>3.0.CO

[2]

2-V

[3] A varying-coefficient cox model for the effect of CA19-9 kinetics on overall survival in patients with advanced pancreatic cancer [J].

Chen, Yuntao ;

Shao, Zhenyi ;

Chen, Wen ;

Xie, Hua ;

Wu, Zhenyu ;

Qin, Guoyou ;

Zhao, Naiqing .

ONCOTARGET, 2017, 8 (18) :29925-29934

[4] CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer [J].

Chiorean, E. G. ;

Von Hoff, D. D. ;

Reni, M. ;

Arena, F. P. ;

Infante, J. R. ;

Bathini, V. G. ;

Wood, T. E. ;

Mainwaring, P. N. ;

Muldoon, R. T. ;

Clingan, P. R. ;

Kunzmann, V. ;

Ramanathan, R. K. ;

Tabernero, J. ;

Goldstein, D. ;

McGovern, D. ;

Lu, B. ;

Ko, A. .

ANNALS OF ONCOLOGY, 2016, 27 (04) :654-660

[5] Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer [J].

Cho, Kyoung-Min ;

Park, Hyunkyung ;

Oh, Do-Youn ;

Kim, Tae-Yong ;

Lee, Kyung-Hun ;

Han, Sae-Won ;

Im, Seock-Ah ;

Kim, Tae-You ;

Bang, Yung-Jue .

ONCOTARGET, 2017, 8 (02) :2329-2341

[6] Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer [J].

Elisei, Rossella ;

Lorusso, Loredana ;

Piaggi, Paolo ;

Torregrossa, Liborio ;

Pellegrini, Giovanni ;

Molinaro, Eleonora ;

Agate, Laura ;

Bottici, Valeria ;

Pani, Fabiana ;

Insilla, Andrea Cacciato ;

Casella, Francesca ;

Ciampi, Raffaele ;

Tognetti, Ilaria ;

Materazzi, Gabriele ;

Basolo, Fulvio ;

Romei, Cristina .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2015, 173 (03) :297-304

[7] Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer [J].

Fornaro, L. ;

Cereda, S. ;

Aprile, G. ;

Di Girolamo, S. ;

Santini, D. ;

Silvestris, N. ;

Lonardi, S. ;

Leone, F. ;

Milella, M. ;

Vivaldi, C. ;

Belli, C. ;

Bergamo, F. ;

Lutrino, S. E. ;

Filippi, R. ;

Russano, M. ;

Vaccaro, V. ;

Brunetti, A. E. ;

Rotella, V. ;

Falcone, A. ;

Barbera, M. A. ;

Corbelli, J. ;

Fasola, G. ;

Aglietta, M. ;

Zagonel, V. ;

Reni, M. ;

Vasile, E. ;

Brandi, G. .

BRITISH JOURNAL OF CANCER, 2014, 110 (09) :2165-2169

[8]

Forones NM, 1999, HEPATO-GASTROENTEROL, V46, P905

[9] Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer [J].

Glimelius, B ;

Hoffman, K ;

Sjoden, PO ;

Jacobsson, G ;

Sellstrom, H ;

Enander, LK ;

Linne, T ;

Svensson, C .

ANNALS OF ONCOLOGY, 1996, 7 (06) :593-600

[10] Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer [J].

Grunnet, Mie ;

Christensen, Ib J. ;

Lassen, Ulrik ;

Jensen, Lars H. ;

Lydolph, Magnus ;

Knox, Jennifer J. ;

McNamara, Mairead G. ;

Jitlal, Mark ;

Wasan, Harpreet ;

Bridgewater, John ;

Valle, Juan W. ;

Mau-Sorensen, Morten .

EUROPEAN JOURNAL OF CANCER, 2015, 51 (11) :1381-1388

← 1 2 3 →